Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Clinical trial NCT04484623 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04484623
- Sponsor
- GlaxoSmithKline
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-01
- Primary completion
- 2024-01-29
- Enrollment
- 302
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.